



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

December 6, 2019

The Manager - CRD
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001
Scrip Code: 524816

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra (E) **Mumbai 400 051**
Scrip Code: NATCOPHARM

Dear Sir,

Sub: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a disclosure of Related Party Transactions for the half year ended September 30, 2019.

Kindly take the above on your records

Thanking you,

Yours faithfully,
For NATCO Pharma Limited


M Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)

NATCO Pharma Limited

(All amounts in ₹ millions)

Related party disclosures, as per Ind AS 24 as on 30-09-2019

(a) Names of the related parties and nature of relationship	
Names of related parties	Nature of relationship
NATCO Pharma Inc., United States of America	Subsidiary company
Time cap Overseas Limited, Mauritius	
NATCO Pharma (Canada) Inc., Canada	
NATCO Pharma Asia PTE Ltd., Singapore	
NATCO Pharma Australia PTY Ltd., Australia	
NATCO Lifesciences Philippines Inc., Philippines	
Natcofarma Do Brasil Ltda., Brazil	Step-down subsidiary company
Time Cap Pharma Labs Limited	Entities in which KMP have control or have significant influence
NATCO Trust	
Mr. V.C.Nannapaneni	Key management personnel ("KMP")
Mr. Rajeev Nannapaneni	
Mr. Sreerama Murthy Gubbala	
Mr. Govinda Prasad Dasu	
Mr. Umamaheshwarrao Naidu Madireddi	
Mr. Venkateswara Rao Thallapaka	
Mr. Sridhar Sankararaman	
Mrs. Leela Digumarti	
Mr. Potluri Prasad Sivaramakrishna	
Mr. Lingarao Donthineni	
Ms. Durga Devi Nannapaneni	
Dr. Ramakrishna Rao	
(b) Transactions with related parties	
For the half year ended 30th September 2019	
Transactions with subsidiaries	
Investment in equity shares	17.7
NATCO Pharma Asia PTE Ltd., Singapore	6.4
NATCO Pharma Australia PTY Ltd., Australia	3.9
NATCO Lifesciences Philippines Inc., Philippines	7.5
Share application money pending allotment	16.2
Time cap Overseas Limited, Mauritius	6.9
NATCO Lifesciences Philippines Inc., Philippines	9.3
Interest on loans	12.1
Time cap Overseas Limited, Mauritius	6.4
NATCO Pharma Asia PTE Ltd., Singapore	2.7
NATCO Pharma Inc., United States of America	3.0
NATCO Lifesciences Philippines Inc., Philippines	0.1
Interest received	5.7
Time cap Overseas Limited, Mauritius	5.7
Sale of products	56.7
NATCO Pharma (Canada) Inc., Canada	51.2
NATCO Pharma Asia PTE Ltd., Singapore	5.5
Transactions with step-down subsidiary	
Sale of products	87.4
Natcofarma Do Brasil Ltda., Brazil	87.4
Transactions with entities where KMP have significant influence	
Time Cap Pharma Labs Limited	2.7
a) Rental expense	2.7



(All amounts in ₹ millions)

	For the half year ended 30th September 2019
NATCO Trust	74.5
a) Donations and CSR activities	74.5
Transactions with KMP	
Short-term employee benefits	32.3
Mr. V.C. Nannapaneni	9.2
Mr. Rajeev Nannapaneni	8.5
Mr. P S R K Prasad	7.3
Dr.Linga Rao	7.3
Rental expenses	2.5
Mr. V.C. Nannapaneni	1.2
Mr. Rajeev Nannapaneni	1.3
Sitting fees	0.6
Mr. Govinda Prasad Dasu	0.1
Mrs. Leela Digumarti	0.1
Mr. Umamaheshwarrao Naidu Madireddi	0.1
Mr. Sreerama Murthy Gubbala	0.2
Mr. Venkateswara Rao Thallapaka	0.1
(c) Balances receivable / (payable)	For the half year ended 30th September 2019
Subsidiaries	585.7
NATCO Pharma Inc., United States of America	118.9
Time cap Overseas Limited, Mauritius	266.2
NATCO Pharma (Canada) Inc., Canada	74.5
NATCO Pharma Asia PTE Ltd., Singapore	117.0
NATCO Lifesciences Philippines Inc., Philippines	9.0
Step-down subsidiary	120.0
Natcofarma Do Brasil Ltda., Brazil	120.0
KMP	(12.6)
Mr. V.C. Nannapaneni	(1.8)
Mr. Rajeev Nannapaneni	(8.8)
Mr. P S R K Prasad	(1.0)
Dr.Linga Rao	(1.0)
Entities where KMP have significant influence	(1.5)
Time cap Pharma Labs Pvt Ltd	(1.5)

